When evaluating treatment responses in HER2-positive breast cancer patients, the pathologic complete response (pCR) rate was 81.3% (n = 13) in patients aged 65 years and older, compared to 47.4% (n = 73)in patients younger than 65 years(p = 0.016). The gene discussed is ERBB2; the disease is breast cancer.